

WEST

Generate Collection

L4: Entry 49 of 59

File: DWPI

Dec 5, 1996

DERWENT-ACC-NO: 1997-034075

DERWENT-WEEK: 200031

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Increasing CD-4 and CD-8 lymphocyte levels in mammals - by admin. of
conjugated linoleic acid, useful for combating adverse effects of tumour necrosis
factor or viral infections

INVENTOR: COOK, M E; DEVONEY, D ; PARIZA, M W ; YANG, X

PATENT-ASSIGNEE:

ASSIGNEE

CODE

WISCONSIN ALUMNI RES FOUND

WISC

PRIORITY-DATA: 1995US-0458956 (June 2, 1995), 1992US-0875896 (April 29, 1992),
1995US-0456988 (June 1, 1995), 1997US-0912614 (August 18, 1997), 1998US-0170604
(October 13, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9638137 A1	December 5, 1996	E	023	A61K031/20
AU 9652535 A	December 18, 1996	N/A	000	A61K031/20
US 5674901 A	October 7, 1997	N/A	008	A61K031/20
EP 831804 A1	April 1, 1998	E	000	A61K031/20
US 5827885 A	October 27, 1998	N/A	000	A61K031/20
US 6020376 A	February 1, 2000	N/A	000	A61K031/20

DESIGNATED-STATES: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK TJ TM TR TT UA UG UZ VN AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU
MC MW NL OA PT SD SE SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

CITED-DOCUMENTS: 7.Jnl.Ref; EP 524796 ; EP 579901 ; EP 641562 ; WO 9606605

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9638137A1	March 14, 1996	1996WO-US03529	N/A
AU 9652535A	March 14, 1996	1996AU-0052535	N/A
AU 9652535A		WO 9638137	Based on
US 5674901A	April 29, 1992	1992US-0875896	CIP of
US 5674901A	June 1, 1995	1995US-0456988	CIP of
US 5674901A	June 2, 1995	1995US-0458956	N/A
US 5674901A		US 5430066	CIP of
EP 831804A1	March 14, 1996	1996EP-0908819	N/A
EP 831804A1	March 14, 1996	1996WO-US03529	N/A
EP 831804A1		WO 9638137	Based on
US 5827885A	April 29, 1992	1992US-0875896	CIP of
US 5827885A	June 1, 1995	1995US-0456988	CIP of
US 5827885A	June 2, 1995	1995US-0458956	Div ex
US 5827885A	August 18, 1997	1997US-0912614	N/A
US 5827885A		US 5430066	CIP of
US 5827885A		US 5674901	Div ex
US 6020376A	June 1, 1995	1995US-0456988	CIP of
US 6020376A	June 2, 1995	1995US-0458956	Div ex
US 6020376A	August 18, 1997	1997US-0912614	Div ex
US 6020376A	October 13, 1998	1998US-0170604	N/A
US 6020376A		US 5674901	Div ex
US 6020376A		US 5827885	Div ex

INT-CL (IPC): A01N 63/00; A23C 9/127; A23C 9/20; A23L 1/29; A61K 31/20; C12P 7/64

RELATED-ACC-NO: 1994-027600;1996-187734 ;1999-105112 ;2000-364422

ABSTRACTED-PUB-NO: US 5674901A
BASIC-ABSTRACT:

Maintaining or elevating the CD-4 and CD-8 cell levels, or preventing or alleviating the adverse effects of a virus or tumour necrosis factor (TNF), in a mammal involves oral or parenteral admin. of conjugated linoleic acid (CLA) or a substance which is converted into CLA in vivo. Also claimed are: (i) the prepn. of CLA by aerobically incubating a suitable Lactobacillus strain in a medium contg. free linoleic acid and nutrients at ambient temp.; and (ii) a CLA-enriched milk prod. made by process (i) using a milk-based medium.

USE - CLA (i.e. 9,11- and/or 10,12-octadecadienoic acid, including geometric isomers) maintains or increases the CD-4 and CD-8 lymphocyte populations to bolster or benefit the immune system, and prevents or alleviates the adverse effects of prodn. or exogenous admin. of TNF and viral infections. Typically CLA can be used to prevent or counteract anorexia and other adverse catabolic effects caused by viral infections or vaccination. Viral infections include those caused by picorna-, toga-, paramyxo-, orthomyxo-, rhabdo-, reo-, retro-, bunya-, corona-, arena-, parvo-, papo-, adeno-, herpes- and pox viruses, e.g. fowl pox in chickens. The undesirable catabolic effects of TNF may occur in patients due to cancer, infectious diseases, vaccinations or exposure to immunostimulants, and may be due to depletion of CD-4 and CD-8 cells caused by a lack of CLA in the diet. CLA may be added to foods or feedstuffs to give a CLA concn. in the diet of 1-10000 ppm, or may be administered in pharmaceutical or veterinary compsns.

ADVANTAGE - CLA is a heat-stable and relatively non-toxic natural food ingredient.

ABSTRACTED-PUB-NO:

US 5827885A
EQUIVALENT-ABSTRACTS:

Method of maintaining or elevating CD-4 and CD-8 cell levels comprises administering orally or parenterally a conjugated linoleic acid or a non-toxic salt (thereof), and/or active ester thereof.

Maintaining or elevating the CD-4 and CD-8 cell levels, or preventing or alleviating the adverse effects of a virus or tumour necrosis factor (TNF), in a mammal involves oral or parenteral admin. of conjugated

linoleic acid (CLA) or a substance which is converted into CLA in vivo. Also claimed are: (i) the prepn. of CLA by aerobically incubating a suitable Lactobacillus strain in a medium contg. free linoleic acid and nutrients at ambient temp.; and (ii) a CLA-enriched milk prod. made by process (i) using a milk-based medium.

USE - CLA (i.e. 9,11- and/or 10,12-octadecadienoic acid, including geometric isomers) maintains or increases the CD-4 and CD-8 lymphocyte populations to bolster or benefit the immune system, and prevents or alleviates the adverse effects of prodn. or exogenous admin. of TNF and viral infections. Typically CLA can be used to prevent or counteract anorexia and other adverse catabolic effects caused by viral infections or vaccination. Viral infections include those caused by picorna-, toga-, paramyxo-, orthomyxo-, rhabdo-, reo-, retro-, bunya-, corona-, arena-, parvo-, papo-, adeno-, herpes- and pox viruses, e.g. fowl pox in chickens. The undesirable catabolic effects of TNF may occur in patients due to cancer, infectious diseases, vaccinations or exposure to immunostimulants, and may be due to depletion of CD-4 and CD-8 cells caused by a lack of CLA in the diet. CLA may be added to foods or feedstuffs to give a CLA concn. in the diet of 1-10000 ppm, or may be administered in pharmaceutical or veterinary compsns.

ADVANTAGE - CLA is a heat-stable and relatively non-toxic natural food ingredient.

US 6020376A

Maintaining or elevating the CD-4 and CD-8 cell levels, or preventing or alleviating the adverse effects of a virus or tumour necrosis factor (TNF), in a mammal involves oral or parenteral admin. of conjugated linoleic acid (CLA) or a substance which is converted into CLA in vivo. Also claimed are: (i) the prepn. of CLA by aerobically incubating a suitable Lactobacillus strain in a medium contg. free linoleic acid and nutrients at ambient temp.; and (ii) a CLA-enriched milk prod. made by process (i) using a milk-based medium.

USE - CLA (i.e. 9,11- and/or 10,12-octadecadienoic acid, including geometric isomers) maintains or increases the CD-4 and CD-8 lymphocyte populations to bolster or benefit the immune system, and prevents or alleviates the adverse effects of prodn. or exogenous admin. of TNF and viral infections. Typically CLA can be used to prevent or counteract anorexia and other adverse catabolic effects caused by viral infections or vaccination. Viral infections include those caused by picorna-, toga-, paramyxo-, orthomyxo-, rhabdo-, reo-, retro-, bunya-, corona-, arena-, parvo-, papo-, adeno-, herpes- and pox viruses, e.g. fowl pox in chickens. The undesirable catabolic effects of TNF may occur in patients due to cancer, infectious diseases, vaccinations or exposure to immunostimulants, and may be due to depletion of CD-4 and CD-8 cells caused by a lack of CLA in the diet. CLA may be added to foods or feedstuffs to give a CLA concn. in the diet of 1-10000 ppm, or may be administered in pharmaceutical or veterinary compsns.

ADVANTAGE - CLA is a heat-stable and relatively non-toxic natural food ingredient.

WO 9638137A

CHOSEN-DRAWING: Dwg.0/4 Dwg.0/2

TITLE-TERMS: INCREASE CD CD LYMPHOCYTE LEVEL MAMMAL ADMINISTER CONJUGATE LINOLEIC ACID USEFUL COMBAT ADVERSE EFFECT TUMOUR NECROSIS FACTOR VIRUS INFECT

DERWENT-CLASS: B04 D13 D16

CPI-CODES: B10-C04E; B11-A01; B14-A02; B14-E11; D03-B; D03-G; D05-C09;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

H7 H722 J0 J011 J1 J171 M225 M231 M262 M281

M320 M416 M431 M720 M782 M903 M904 M910 N131 N161

N512 P210 P714 Q233

Specific Compounds

00206M 00206P

Registry Numbers

0206P 0206U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0206P; 0206U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1997-010590